All In Biotech

Drug Trial Radar · NCT05995405

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH

Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective, Randomized Trial

Last checked: Nov 19, 2026Latest source record: Oct 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 20, 2023

Primary completion

Dec 2024

Study completion Dec 2024

Sponsor

Lead sponsor
Grace Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Aug 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.

Conditions

  • Aneurysmal Subarachnoid Hemorrhage (aSAH)

Interventions

  • GTX-104Drug

    Nimodipine IV infusion

  • Nimotop 30 MG Oral CapsuleDrug

    Oral nimodipine capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence (% or proportion) of subjects with at least one episode of clinically significant hypotension with a reasonable possibility that GTX-104/oral nimodipine caused the event, according to the Endpoint Adjudication Committee.Time frame: 90 days

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • Brain and Spine Neurological Institute

    Phoenix, Arizona

  • Community Regional Medical Center

    Fresno, California

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Emory University School of Medicine Emergency Neurosciences

    Atlanta, Georgia

  • Northwestern Feinberg Pavillion Neuro and Spine ICU

    Chicago, Illinois

  • Indiana University Health Methodist Hospital

    Indianapolis, Indiana

  • University of Kentucky Hospital

    Lexington, Kentucky

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Washington University

    St Louis, Missouri

  • The Mount Sinai Hospital

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Duke University

    Durham, North Carolina

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Methodist University Hospital

    Memphis, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Health Science Center at Houston

    Houston, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.